A new drug targeting KRAS has been developed for pancreatic cancer treatment, offering hope for patients with the disease. The drug, which has been the subject of research, may extend survival rates for those with metastatic pancreatic adenocarcinoma. Reports suggest the treatment could potentially double survival time, although details about its effects and availability are still emerging.